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Natural peptides selected by diabetogenic
DQ8 and murine I-Ag7 molecules show
common sequence specificity
Anish Suri,1 James J. Walters,2 Michael L. Gross,2 and Emil R. Unanue1
1Departments

of Pathology and Immunology and 2Department of Chemistry, Washington University School of Medicine, St. Louis, Missouri, USA.

In this study, a large number of naturally processed peptides was isolated and identified from the human
diabetes-susceptible class II MHC molecules HLA-DQ8 (DQA1*0301,DQB1*0302) and from murine I-Ag7
species, both of which are expressed in genetically identical APC lines. The peptides presented during the
processing of autologous proteins were highly selective in showing sequence specificity, mainly consisting
of 1 or more acidic residues at their C terminus. Testing for binding to the MHC molecules revealed that the
position 9 (P9) acidic residues of the peptides contributed decisively to binding. For HLA-DQ8, the P1 residue, which was also an acidic amino acid, influenced binding positively. Both HLA-DQ8 and I-Ag7 selected
for common peptides that bound in the same register. There was no evidence for selection of peptides having
nonspecific or promiscuous binding. Thus, diabetogenic class II MHC molecules are highly selective in terms
of the peptides presented by their APCs, and this is governed by the features of their P9 anchor pocket. These
results are in striking contrast to those from studies examining synthetic peptide or phage display libraries,
in which many peptides were shown to bind.
Introduction
The most important genes responsible for the onset of type 1 diabetes mellitus (T1DM) are those encoding the class II MHC alleles
(1–3). In particular, the biochemical features of diabetogenic class
II MHC molecules determine binding of autoantigenic peptides
that ultimately trigger islet β cell–reactive T cells. In both humans
and NOD mice (4), a notable feature of diabetes-related class II
MHC alleles is the expression of a nonaspartic acid residue at
position 57 of the β chain: an alanine in the case of the human
HLA-DQ2 and HLA-DQ8 molecules (hereafter referred to as DQ2
and DQ8, respectively) and a serine in the case of the NOD class II
MHC molecule I-Ag7 (5–7). In contrast, most other class II MHC
alleles express a conserved aspartic acid at β57 that pairs with an
arginine at α76, defining the position 9 (P9) pocket of the peptide
binding groove. Moreover, in humans, there are other alleles, such
as HLA-DR3 and HLA-DR4, that in association with the DQ molecules increase the genetic risk for T1DM (8, 9).
The structure of both the I-Ag7 (10, 11) and DQ8 (12) molecules
was solved by x-ray crystallography. I-Ag7 showed a P9 anchor
pocket that was shallow, wide, and more open toward the C terminus as a result of the β57Ser and β56His. Subsequent studies
established that the P9 pocket was most crucial in determining the
selection of peptides during processing of natural proteins by APC
(13, 14). Peptides selected by I-Ag7 contained acidic-rich C termini
that interacted with the P9 pocket and often contained multiple
C-terminal acidic residues that increased their binding affinity
(13). APCs expressing a modified I-Ag7, wherein the β57Ser was
changed to the conserved aspartic acid, did not favor peptides with
C-terminal acidic residues (13).
Nonstandard abbreviations used: MS, mass spectrometry; MS/MS, tandem mass
spectrometry; P9, position 9; SCX, strong cation exchange; TFA, trifluoroacetic acid.
Conflict of interest: The authors have declared that no conflict of interest exists.
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Wiley’s group resolved the protein crystal structure of the DQ8
molecule bound to an insulin peptide, demonstrating the similarities of its P9 pocket to that of I-Ag7 (12). However, the spatial
and biochemical features of the other binding pockets of DQ8
are distinct. The DQ8 P4 pocket is very large and accommodates
bulky residues such as tyrosines, while in I-Ag7, it is shallow and
favors small to medium-sized hydrophobic residues, disfavoring
large, bulky residues. Similarly, the P1 pocket of DQ8 contains an
arginine at α52 (in contrast to an isoleucine in the case of I-Ag7),
which forms an ion pair with an acidic amino acid from the
peptide at P1. Our previous studies on peptide selection by I-Ak,
which also contains α52Arg, revealed that most of the high-affinity peptides selected by this haplotype contained an acidic residue
at P1 (15, 16). Thus, with respect to the P1 pocket, DQ8 resembles
I-Ak more closely than I-Ag7. However, the precise contribution of
each of these pockets in influencing the repertoire of peptides
selected by DQ8 remains unclear.
Previous studies analyzing naturally processed peptides selected
by human diabetogenic class II MHC molecules are limited and
have given ambiguous results. In the first study by Chicz et al.,
few peptides were identified from DQ8 APCs ranging from 13–74
amino acids in length. These did not exhibit a consensus binding
motif and were not analyzed extensively for their binding features
(17). A second study, by Godkin et al., utilized pool sequencing
to identify DQ8-bound peptides. This report suggested the presence of both acidic and basic amino acids at P4 (aspartic acid),
P6 (arginine), and P9 (arginine and glutamic acid) (18). Concerning the peptide binding motif for DQ8 and DQ2, some reports
suggested the preference for an acidic P9 anchor, while others did
not (17–29). Moreover, recent reports examining binding with synthetic peptides indicated that the murine and human diabetogenic
molecules bound epitopes of various specificity (24, 30, 31).
Information on the peptides naturally selected during processing will help in understanding the role of MHC in autoimmunity as well as in predicting potential diabetogenic peptides.
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Table 1
Class II MHC molecules and background genes of cell lines
APC
NOD.C3
NOD.DQ8

Class II MHC

β57

Background

I-Ag7
DQ8

Ser
Ala

NOD
NOD

APC lines were generated by fusion of LPS-activated splenocytes
from NOD or transgenic NOD.DQ8 mice to the M12.C3 B cell lymphoma partner line.

Naturally processed peptides represent the physiological substratum for CD4 T cell recognition: they represent what the APC
prefers to select and display to the extracellular milieu. What are
the chemical features of the natural peptides bound and selected
by DQ8 molecules during the processing of self proteins? What
are the binding motifs of such naturally selected peptides and
the anchor residues that contribute to binding and selection? Are
there peptide families that are naturally selected by both DQ8
and I-Ag7 molecules, and if so, is the mode of binding identical
between the two? To answer these basic questions in a definitive way, we isolated naturally processed peptides from APC
lines expressing either DQ8 or I-Ag7. The APC lines were identical, except for the class II molecules, which allowed us to directly
compare the repertoire of peptides selected by them. The large
data sets of naturally processed peptides indicated a high degree
of specificity of peptide selection exhibited by DQ8 — of note was
the presence of multiple C-terminal acidic residues especially at
P9 and to a lesser degree at P1. In contrast to results of studies
using synthetic peptide libraries, there was little peptide promiscuity for DQ8 or for I-Ag7 proteins. We provide the first direct
evidence that identical peptide families were naturally selected by
both DQ8 and I-Ag7 and bound in the same register, which indicates a common biochemical outcome of the antigen processing
and presentation pathways.
Results
Generation and characterization of APC lines
APC lines were generated on identical genetic backgrounds
expressing either DQ8 or I-Ag7 (Table 1). FACS analysis indicated that the I-Ag7–expressing NOD.C3 cell line had about
8-fold more cell surface class II MHC molecules than the NOD.
DQ8 cell line (Figure 1). This difference in class II MHC levels
also correlated with the amounts of peptides recovered from
each cell line; i.e., more peptides were isolated from I-A g7 than
from DQ8 (Supplemental Tables 1 and 2, and see following sections; supplemental material available online with this article;
doi:10.1172/JCI25350DS1).
Features of naturally processed peptides
Naturally selected peptides, from I-Ag7 and DQ8, were isolated and
sequenced by tandem mass spectrometry (MS/MS) analyses. The
class II MHC molecules select for peptides in “families,” each sharing a common 9-amino-acid core, which interacts with the MHC
binding groove from P1 to P9, along with varying lengths of flanking residues in the N and C termini (for example, see refs. 13, 32).
A total of 206 peptides representing 108 families were isolated
from DQ8 (Table 2 is a summary; the entire library of peptides is
presented in Supplemental Table 1). We previously reported on

I-Ag7–bound peptides but repeated the isolation in the current
study in order to compare experiments done with the same cell
line and in parallel with the examination of peptides from DQ8:
301 peptides representing 115 distinct families were isolated from
I-Ag7 (Table 3 is a summary; Supplemental Table 2 includes all the
information). Peptides from both were derived from proteins present on the cell membrane, vesicular compartment, and cytosol, as
well as the extracellular milieu.
Interestingly, 18 of the 108 peptide families (or 17%) from DQ8
were also selected by I-A g7 (Table 4 and marked by asterisks in
Supplemental Table 1). The abundance of some of the common
peptide families was comparable in the 2 molecules, while others
were dominant in one compared with the other (see Supplemental Tables 1 and 2). For example, from DQ8, 7 members of the
E2B 112–126 peptide family were identified, while from I-Ag7,
16 members were sequenced (Supplemental Tables 1 and 2).
Nonetheless, the finding of common peptide families in I-Ag7
and DQ8 was especially surprising, since both proteins exhibit
only 60–70% similarity at the amino acid level between their α
and β chains. In contrast, I-Ag7 is approximately 94% similar to
I-Ad, but the naturally processed peptides selected by each were
entirely distinct (13, 14). Moreover, peptides selected by a mutant
I-Ag7 molecule called I-Ag7PD, in which residues 56 and 57 of the
β chain were replaced by those from the I-Ad allele, did not overlap with those selected by I-Ag7 (13). Note that most of the common peptides exhibited the presence of an acidic amino acid at
P9 (Table 4). The relevance of this observation with regard to the
binding motif is discussed in the following section.
Binding motif: DQ8 versus I-Ag7
The naturally processed peptides from DQ8 and I-Ag7 were aligned
on the basis of a favorable 9-mer core (as shown in Supplemental
Tables 1 and 2). The compiled results of such analyses established
the preferred binding motif for both diabetogenic class II MHC
molecules, which we detail below. DQ8 and I-Ag7 selected for peptides that contained acidic amino acids toward their C terminus
(Figure 2). Many peptides from both contained runs of double or
triple acidic residues toward the C terminus. It was shown previously that multiple C-terminal acidic residues cooperated to
increase peptide binding affinity to I-Ag7 (13). In addition, DQ8

Figure 1
Class II MHC expression among APC lines. NOD.C3 and NOD.DQ8
cells were stained with anti–I-Ag7 or anti-DQ8 mAb (gray lines), respectively, and then analyzed by FACS. Black lines indicate the isotype
control for each cell line.
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Table 2
Examples of naturally processed peptides selected by DQ8
Peptide

1

E25B protein 112–126
Y
Q
Superoxide dismutase 90–103		
A
TRAIL receptor 2 364–380
G
R
Lamp I 129–144
I
Y
Transferrin receptor 334–347		
I
Cyclophilin C–associated protein 325–340
V
D
Serine proteinase inhibitor 90–103			
14-3-3 ζ 28–41		
S
Nicastrin 65–78		
I
IL-6 signal transducer 311–324		
W

T
G
F
T
P
Q
L
V
S
S

4

E
D
Y
D
Q
S
D
E
D
E

I
K
T
M
V
W
R
T
G
E

E
G
Q
S
T
T
F
Q
T
A

N
V
N
T
I
E
S
G
G
S

I
A
A
T
S
T
N
A
V
G

6
K
N
A
D
R
I
M
E
I
T

I
V
A
I
A
A
A
L
H
T

9
F
S
Q
K
A
S
S
S
V
Y

E
I
P
A
A
H
A
N
V
E

E
E
E
D
E
E
E
E
E
D

D
D
T
I
K
D
E
E
K
R

A
R
G
N
L
I
N
R
E
P

P
K

G

E
Q

The favorable anchor residues at P1, P4, P6, and P9 are underlined. The entire list of naturally processed peptides selected by DQ8 is shown in Supplemental Table 1.

DQ8 binding motif. The P1 pocket of DQ8 exhibited a preference
for acidic amino acids (about 42% of residues at P1 were either glutamic acid or aspartic acid; Figure 3A), which was consistent with the
structural aspects. Besides these, the P1 pocket also accommodated a
variety of residues with the noticeable exception of basic amino acids,
which would be electrostatically disfavored at this position. P4 was
dominated by small hydrophobic or polar residues — alanine, serine,
glycine, and threonine constituted 53% of amino acids at P4; while
P6 favored alanine, valine, and serine, which made up 52% of the
residues (Figure 3A). The P9 pocket of DQ8 was almost exclusively
dominated by acidic amino acids — 84% of them (Figure 3A).
I-Ag7 binding motif. P1 of I-Ag7 accommodated a variety of residues,
including polar, charged, and hydrophobic amino acids. P4 and P6
were dominated by the presence of small to medium-sized hydrophobic amino acids in addition to polar residues (leucine, isoleucine, and
valine represented more than 60% of amino acids at P4; while alanine,
serine, valine, and glycine represented more than 60% of residues at
P6) (Figure 3B). Both P4 and P6 disfavored bulky or basic amino
acids. P9 was highly biased for the presence of acidic amino acids
(∼90% of residues at P9 were glutamic acid or aspartic acid; Figure 3B),
results that are akin to those of our prior studies (13, 14).

also showed a slight preference for acidic amino acids at the N
terminus (Figure 2), a finding consistent with the biochemical
features of the P1 pocket of DQ8 discussed above (12).
The relative abundance for naturally processed peptides selected by DQ8 varied greatly: the most abundant peptide family was
1,200-fold more abundant than the least; similarly, for I-Ag7, the
difference was about 3,000-fold (see Supplemental Tables 1 and
2 for abundance). There was also no relationship between the
abundance of peptides and their binding motifs (Supplemental
Tables 1 and 2); i.e., peptide families with favorable binding cores
were present in varying amounts. In addition, binding affinity also
did not correlate with abundance, for example, even though the
peptide from superoxide dismutase 1 protein 90–103 bound about
15-fold better to DQ8 than the epitope from DQ α chain 39–52,
it was present in one-tenth the amount of the DQ α chain peptide
(Table 5 and Supplemental Table 1; see also the following section).
Similar results were obtained in our earlier analysis of peptides
bound to I-Ag7, I-Ad, I-Ag7PD, and I-Ak (13, 14) and in the analysis of
class I MHC peptides by Engelhard’s laboratory (33) and ours with
Kd-bound peptides. Other parameters such as the levels of protein
expression, their turnover rates, and their accessibility to the MHC
pathways of antigen processing and presentation must impact
the final outcome of abundance and peptide selection. These features may become very relevant in situations of pathogen-specific
immune responses or autoimmune responses.

Binding analyses
All 14 peptides tested in the binding assay bound to soluble DQ8,
which confirmed that these were bona fide epitopes selected by

Table 3
Examples of naturally processed peptides selected by I-Ag7
Peptide

1

E25B protein 112–126		
Y
Q
Cyclophilin C–associated protein 325–340		
V
D
Actg2 protein 70–84		
Y
P
HDL binding protein 20–35		
V
P
IL-21 receptor 350–366
I
P
L
B lymphocyte antigen CD19 19–33				
Cathepsin D 65–77			
E
Ndfip 1 protein 84–98		
T
E
Transferrin receptor 34–47			
S
Phosphoglycerate kinase 76–89		
W
E

T
Q
I
Q
A
R
P
A
H
A

I
W
E
Q
A
P
V
T
V
F

E
S
H
I
G
Q
S
I
E
A

4
E
T
G
K
Q
K
E
P
M
R

N
E
I
V
A
S
L
L
K
G

I
T
I
A
V
L
L
V
L
T

6
K
I
T
T
S
L
K
P
A
K

I
A
N
L
A
V
N
G
A
S

9
F
S
W
N
Y
E
Y
R
D
L

E
H
D
S
S
V
L
D
E
M

E
E
D
E
E
E
D
E
E
D

D
D
M
E
E
E
A
D
E
E

A
I
E
E
R
G

E
N
D
G

F
N

The favorable anchor residues at P1, P4, P6, and P9 are underlined. The entire list of naturally processed peptides selected by I-Ag7 is shown in
Supplemental Table 2.
2270
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Table 4
List of naturally processed DQ8 peptides that were also selected by I-Ag7
Peptide

1

Ran 25 kDa ras-related protein 19–34					 H D L
E
Lymphocyte cytosolic protein 1 508–519						 E D
I
14-3-3 ζ 228–245
W T S D T Q G D
Ubqln2 protein 81–94					 M R Q L
E25B protein 112–126A					 Y Q T
I
Hnrpr protein 592–601									
SNRPF protein 128–143					 Y I R G
Envelope protein 497–512					 V S A L
Cytochrome b5 precursor 136–146							 Y R
Wbscr5 146–162				 K P S T P
Small nuclear ribonucleoprotein polypeptide G 48–59							 M A
Eef1a1 protein 191–200									
Translocase of mitochondrial membrane 7 36–50					 F T R G
Apolipoprotein A-IIA					 G S E
L
Elongation factor 1-β homolog 213–225							 Y V
G-3-P dehydrogenase 296–309					 R V V D
Cyclophilin C–associated protein 325–340A				
V D Q W
CD23 218–231A				 D L K G R

V
G
E
I
E
Y
V
E
H
E
T
V
A
Q
Q
L
S
L

4
A
G
A
M
E
Q
E
K
F
S
S
P
D
T
S
M
T
V

Q
G
E
A
N
D
E
S
W
G
G
I
P
Q
M
A
E
S

T
Q
A
N
I
T
E
L
A
V
Q
S
G
A
D
Y
T
I

6
T
K
G
P
K
Y
E
T
D
E
Q
G
M
K
V
M
I
H

A
V
E
Q
I
G
E
S
S
D
N
W
P
A
A
A
A
S

9
L
N
G
M
F
Q
D
L
K
F
N
N
E
Y
A
S
S
Q

P
D
G
Q
E
Q
G
S
S
E
I
G
P
F
F
K
H
K

D
D
E
Q
E
W
E
E
S
D
G
D
S
E
N
E
E
E

E

D

D

N
L
D A
K
M R
V V

E
L

Y
M
N
V
K
K
E
D
Q

Q

N

L
T
I

Q

I
D

E

The peptides are aligned on the basis of the preferred anchor residues at P1, P4, P6, and P9. APeptides that were shown to bind to both DQ8 and I-Ag7.

this MHC molecule (Table 5). Most peptides bound with a relative affinity in the range of 0.6–5.0 µM, and 2 were poor binders
(IC50 > 33.0 µM; Table 5). Four peptides tested in this assay were
previously isolated from I-Ag7 and shown to bind to it (Table 5)
(13). The relative binding affinity of these 4 common peptides was
comparable between I-Ag7 and DQ8 (Table 5).
The peptide-binding register of the natural epitopes to DQ8 was
examined by testing peptides with single amino acid changes in
order to confirm the usage of preferred anchor residues (Table 6).
Placing lysine, a strong hindering residue for P1, P4, P6, and P9, at
different positions in the peptide sequence helped indicate which
position was normally being used.
E25B peptide. The E25B 112–126 peptide family was selected
by both DQ8 and I-Ag7. To identify the P9 anchor, each of the 3
C-terminal acidic amino acids was changed to a lysine. Changing the
Glu123 and Asp125 to a lysine had no effect on binding to either
DQ8 or I-Ag7 (Table 6). However, when Glu124 was mutated, the
peptide bound very poorly to both, which demonstrated that this
residue was being preferentially used as the P9 anchor. To confirm that this was indeed the binding register, i.e., with Glu124,
the putative P4 (Ile119) or P6 (Ile121) was changed to a lysine.
A basic amino acid at P4 or P6 also negatively affects binding:
either change also resulted in a loss of binding (Table 6). (The lack
of a binding register having Glu123 or Asp125 as the P9 anchor

residues is explained by unfavorable residues at P4 and/or P6: if
Glu123 was the P9 anchor, then Lys120 would be the P6 anchor;
if Asp 125 was the P9 anchor, then Lys120 and Phe122 would be
the P4 and P6 anchors, respectively.) Of note is that changing the
multiple C-terminal acidic residues to alanine only resulted in a
modest decrease in binding to both DQ8 and I-Ag7 — an alanine,
although not preferred at P9, was well tolerated (10, 11). In the
case of DQ8, changing the P1 Glu116 to a lysine also resulted in
about a 4- to 5-fold loss of binding (Table 6). Thus, although DQ8
prefers acidic amino acids at P1 and P9, the effect on binding is
more evident for P9 than for P1 (Table 6). Moreover, these mutational analyses taken together established that the E25B 112–126
peptide binds to both I-Ag7 and DQ8 in exactly the same register.

Figure 2
Acidic amino acid distribution among naturally processed peptides
selected by I-Ag7 and DQ8. Each peptide was scored for the presence of either an aspartic acid or glutamic acid residue starting at the
most C-terminal position, which was assigned position 1 in the figure.
Thus, by this scheme, the second most C-terminal residue would be
position 2, the third would be position 3, and so on. Note that peptides
selected by both I-Ag7 and DQ8 contained acidic amino acids toward
their C termini. In addition, peptides selected by DQ8 also exhibited
the biased presence of acidic amino acid toward their N terminus. The
dotted line represents the background frequency of the presence of
acidic amino acids.
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Table 5
Binding analysis of naturally processed peptides to DQ8
Peptide

AA sequence

MHC II Eα 51–65
Superoxide dismutase 1 90–103
Cyclophilin C–associated protein 325–340
E25B protein 112–126
TRAIL receptor 2 364–380
Transferrin receptor 334–347
Nicastrin 65–78
Na,K-ATPase α-1 subunit 400–413
Lamp I 129–144
Apolipoprotein A-II 31–46
CD23 219–231
MHC class II antigen, DQ α chain 39–52
Polyubiquitin 6–21
Serine (or cysteine) proteinase inhibitor 90–103
APeptides

that were tested for binding in a previous study by Suri et al. (13).

DQ8

I-Ag7 A

1.0
2.0
0.6
0.8
1.7
3.8
1.0
>33.0
7.8
4.6
5.9
>33.0
1.0
2.4

–
–
3.3
0.4
–
–
–
–
–
1.8
3.1
–
–
–

Discussion
The diabetogenic-propensity
class II MHC molecules exhibited
a very high degree of specificity
with regard to natural peptides
selected during processing of the
proteins. Neither DQ8 nor I-Ag7
molecules were promiscuous in
terms of the peptides selected during processing, and for both, the
P9 anchor played the dominant
role in establishing the register
of peptide binding. These characteristics explain the commonalities of peptide selection between
the murine and human class II
molecules, which are structurally
similar at the P9 anchor site but are unique at the other positions.
Also worthy of emphasis is the presence of multiple C-terminal
acidic residues — 39% and 46% of peptide families from DQ8 and
I-Ag7, respectively, contained more than 1 C-terminal acidic residue, some in pairs and others separated by 1 amino acid (Figure 2).
In addition, for DQ8 molecules, the P1 anchor (mostly aspartic
or glutamic acid) cooperated with the P9 acidic amino acid to
increase binding affinity (Table 6).
We emphasize these results because other studies, including
an early one from our laboratory (34), claimed the contrary,
that there was a noticeable lack of specificity of I-Ag7 or DQ8
molecules for peptides (24, 30, 31). These data were obtained by
examining synthetic peptides or phage display libraries thought
to represent the antigenic epitopes and equivalent to the natural
peptides. The results indicated that the key primary anchor positions for DQ8 and I-Ag7 were tolerant to many amino acids, an
issue which is undisputed. An excellent example supporting this
argument is the P9 pocket of DQ8 and I-A g7, which accommodated acidic or small hydrophobic/polar residues. However, the
results indicated here by the analyses of naturally selected peptides portray a very different outcome characterized by exquisite
selectivity and an overwhelming bias for the presence of acidic
amino acids at this position (Figure 3, A and B).
The explanations for this important discrepancy may be along 2
lines: either during the processing of the proteins to generate the
peptide-MHC complex, the peptides with nonacidic C-terminal
residues were not bound (in general the peptides with non–terminal acidic residues tend to bind less well, although this reduction
is not a striking feature); or if they did bind, they were edited by
HLA-DM (or H2-DM) and/or lost during the intracellular trafficking of the MHC molecules. Work that is in progress indicates
that peptides with nonacidic residues dissociated at a higher rate
from the MHC molecules at neutral pH. Regardless of the explanation, the repertoire of natural peptides represents those that are
physiologically relevant for the T cell response, which is especially
important in the case of aberrant immune responses mounted
against self. (In addition, knowing the sequence of the natural peptides establishes other features important for T cell recognition,

FDGDEIFHVDIEKSE
AGKDGVANVSIEDR
VDQWSTETIASHEDIE
YQTIEENIKIFEEDA
GRFTYQNAAAQPETGPG
IPVQTISRAAAEKL
ISGDTGVIHVVEKE
ADTTENQSGVSFDK
IYTMDSTTDIKADINK
GSELQTQAKAYFEKTQ
DLKGRLVSIHSQKEQD
YQSYGPSGQYSHEF
KTLTGKTITLEVEPSD
LRDFSNMASAEENQ

MHC II Eα peptide. Three acidic amino acids are found at the C
terminus of the Eα51–65 peptide: Asp60, Glu62, and Glu65. It
seemed unlikely that Asp60 or Glu65 could be used as P9 anchors
since they generated binding registers that contained unfavorable residues at P4 and P6 (as described above) (Table 6). Glu62
emerged as the likely candidate for the P9 anchor and when
changed to a lysine generated a nonbinding peptide (Table 6). The
binding register was further ascertained by mutating the putative P4 and P6 (Phe57 and Val59, respectively) to a lysine — both
changes resulted in a complete loss of binding (Table 6). Note that
changing the amino acids at P4 and/or P6 singly to an alanine did
not have a noticeable affect on binding, since these residues are
acceptable at either of these positions. Also, changing the acidic P1
anchor (Asp54) to a lysine or alanine only slightly affected binding;
however, an alanine at P1 in conjunction with P9 reduced binding
10-fold (Table 6). This was consistent with the results with the E2B
peptide; i.e., an acidic residue at P9 contributed more to binding
than the same residue at P1.
Superoxide dismutase 1 peptide. In the superoxide dismutase 1
peptide, Glu101 was the P9 anchor; changing this to lysine generated a nonbinding peptide (Table 6). Mutating the P9 Glu101 to
an alanine decreased binding about 3-fold, and this was enhanced
when the P1 Asp93 was also changed to an alanine (>15-fold loss
of binding) (Table 6). Substituting only the P1 Asp93 to a lysine
had a very modest effect on binding. The register was further confirmed by changing the P6 Val98 to a lysine, which again resulted
in a complete loss of binding (Table 6).
TRAIL receptor 2 peptide. In the case of the TNF-related apoptosisinducing ligand (TRAIL) receptor 2 peptide, the only C-terminal
acidic amino acid was a Glu376, which when mutated to a lysine
resulted in about a 4-fold loss of binding (Table 6). Changing the P1
Tyr368 to lysine or an alanine had a small negative effect, but replacing both P1 and P9 by lysines decreased binding about 15-fold,
which indicates a cooperative interaction between the P1 and P9
anchor residues (Table 6).
Nicastrin peptide. In the nicastrin peptide, changing the P9
Glu76 to a lysine lowered binding about 18-fold, but the same
mutation at P1 (Asp68→Lys) resulted in a complete loss of
2272

Binding (µM)

binding (Table 6). Thus, the P1
acidic anchor contributed more
to binding affinity than the P9
acidic residue (Table 6).
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epitopes that may be displayed by I-Ag7 and DQ8
(37–39). Our data supports the hypothesis that
the NOD mouse is highly valid for identification
of putative pathogenic T cell epitopes and for testing such peptides for their ability to establish disease-preventive protocols.
Methods
Cell lines, antibodies, and isolation of peptides
The M12.C3 B cell lymphoma was fused to LPSactivated splenocytes from wild-type NOD (I-A g7)
or transgenic NOD.DQ8 (DQ8+I-Ag7–) (40) mice
to generate the NOD.C3 or NOD.DQ8 cell lines,
respectively. Usage of mice was approved by the
Division of Comparative Medicine at Washington
University (St. Louis, Missouri, USA). This protocol generated APC lines on identical genetic backgrounds, although variation due to chromosomal
differences between the 2 cell lines was not excluded.
Both cell lines were maintained in DMEM supplemented with 10% calf serum. For isolation of peptides, NOD.C3 and NOD.DQ8 cells were expanded
in roller bottles to obtain 5 × 109 to 10 × 109 cells.
Following detergent lysis, the MHC molecules were
affinity purified using the AG2.42.7 (for anti–I-Ag7)
or 9.3.F10 (for anti-DQ8) antibodies conjugated to
sepharose beads, as previously described (13, 14).
Peptides bound to class II MHC molecules were acid
eluted using 0.1% trifluoroacetic acid (TFA), separated from the class II MHC proteins, dried down,
and then analyzed by mass spectrometry (MS) as
described below.
Generation of soluble DQ8 molecules
Construction of DQ8 expression vector. The cell line
NOD.DQ8 containing the DQ8 α and β ectodomains were cloned into the vector pCR2.1
(Invitrogen Corp.) and modified by PCR extenFigure 3
sion to include the Fos and Jun leucine zipper
Distribution of amino acids at the P1, P4, P6, and P9 positions. (A) Peptide binding domains. The domains of both DQ8 chains were
motif for DQ8. The P1 through P9 amino acids of the naturally processed peptides
subcloned into the baculovirus expression vector
listed in Supplemental Table 1 were aligned to identify the preferred residues at P1,
g7
P4, P6, and P9. (B) Peptide binding motif for I-A . The P1 through P9 amino acids pFastBac Dual (Invitrogen Corp.). The Fos and
of the naturally processed peptides listed in Supplemental Table 2 were aligned to Jun leucine zippers were attached to the C terminus of each chain through a polylinker containing
identify the preferred residues at P1, P4, P6, and P9.
thrombin cleavage sites (ANLVPRGSTAPS). The α
chain carries a 6-His-tag at the end of Fos. The β
such as the relevance of flanking residues in the display of the T chain has a covalently linked human CLIP-containing sequence
cell receptor contact residues [ref. 35].) The contrasting results (SKMRMANPLLMQA) attached at its amino terminus by a glyindicate the problems in depending only on data obtained from cine- and serine-rich linker containing a thrombin cleavage site
peptides thought to represent the natural epitopes. Vaccination (GGGGSLVPAGSGGGGSGS).
with microbial or autoimmune peptides without knowing their
Expression of DQ8 in insect cells. High Five insect cells were infected
display may be a fruitless venture.
with baculovirus expressing the DQ8 chains. Cells were grown to a
Finally, our results provide more evidence, this time direct, of density of 2 × 106 cells/ml in serum-free medium (JRH Biosciences)
the selection of identical epitopes between APCs bearing DQ8 or in baffled flasks before infection at an MOI of 10 and then were
I-Ag7 molecules. Many previous studies identified common pro- incubated for 72 hours at 27°C. The clarified medium was conteins (such as glutamic acid decarboxylase, insulin, heat shock centrated and exchanged into 50 mM NaH2PO4 (pH 8.0), 10 mM
proteins, etc.) as targets of autoimmunity in NOD mice and imidazole, and 0.5 M NaCl using 10 kDa Centramate tangential
humans (reviewed in refs. 1, 36). In addition, previous reports flow filtration system (Pall Corp.). The concentrated supernatant
analyzing T cell responses have indirectly alluded to common was passed by gravity over a 5-ml bed of Ni-NTA beads (QIAGEN).
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Table 6
Mutational analyses of naturally processed peptides to identify the binding register
Peptide

Sequence

E25B protein 112–126

MHC II Eα 51–65

Superoxide dismutase 1 90–103

TRAIL receptor 2 364–380

Nicastrin 65–78

Binding (µM)

Y Q T I E E N I K I F E E D A
----------------------K-----------------------------K-----------------------------K-------------------------A---------------------------A-A-----------------------A-A-A-------------------K-----------------------K---------------------K-------------------F D G D E I F H V D I E K S E
----------------------K-----------K---------------------------A---------------------------A---------------A-----------K---------------K-----------------K---------------------------A-------------------------------K---------------------------A-----------A G K D G V A N V S I E D R
----------------------K---------------------------A---------------------------A-A---------K---------------------------A---------------------------K---------------K-----------A---------------A---------------------K---------------------------A-----------G R F T Y Q N A A A Q P E T G P G
------------------------K-------------------------------A---------------K-------------------------------A-------------------------------K---------------K---------------A---------------A-------I S G D T G V I H V V E K E
----------------------K-------------------------A---------K-------------------------A-------------------------K---------------K----

DQ8
0.8
1.0
>33.0
1.7
1.8
2.5
1.7
>33.0
>33.0
3.8
1.0
NB
2.8
2.0
10.7
NB
10.7
3.3
NB
3.1
2.0
NB
7.8
7.7
5.1
1.8
NB
>33.0
NB
2.8
1.7
6.9
1.0
3.7
1.7
26.4
3.1
1.0
18.7
4.3
NB
2.3
NB

I-Ag7 A
0.4
0.3
12.0
0.2
0.3
0.5
2.3
9.9
66.0
ND

The 9-mer binding core mapped for each peptide is underlined. ABinding was tested in a previous study by Suri et al. (13). ND, not determined; NB, non-binder.

The column was washed first with 50 mM NaH2PO4 (pH 8.0),
0.5 M NaCl, and 50 mM imidazole and then eluted with 50 mM
NaH2PO4 (pH 8.0), 0.5 M NaCl, and 250 mM imidazole. The fractions containing the DQ8 were pooled and dialyzed to 10 mM
HEPES, 150 mM NaCl (pH 7.2).
2274

Binding analysis
Briefly, 1.0–1.5 µg of purified baculovirus DQ8/CLIP was treated with 0.1 units of thrombin to cleave both the zipper tails and
peptide linker (Novagen) and simultaneously incubated with
0.125 pmol of 125I-radiolabeled reference hemagglutinin peptide
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(FESTGNLIAPEYGFKISY), labeled by the chloramine T method,
as described previously (41), and increasing doses of unlabeled
peptides in 40 mM 2-[N-Morpholino]ethanesulfonic acid, 150
mM sodium chloride, pH5.5. The hemagglutinin peptide has
previously been used as an indicator peptide in DQ8 binding
assays (26). Binding reactions were incubated for 48 hours at
37°C in 30- to 32-µl volumes. Complexes were purified from
free peptide using gel filtration Bio-Spin columns (Bio-Rad Laboratories). The percentage of bound peptide was evaluated by
gamma counting. The amounts of peptides bound in the reactions were about 15–20% that of the input radiolabeled standard
peptide. Relative binding data refers to the amounts required to
inhibit the binding of the reference peptide by 50%. Individual
binding results with the reference peptide varied less than 10%
from the averaged value.
Two-dimensional liquid chromatography–MS
MHC peptide extracts from NOD.DQ8 and NOD.C3 lines were
treated identically. Each was analyzed by on-line reverse phase
liquid chromatography–MS (RPLC-MS) and MS/MS and additionally by off-line strong cation exchange (SCX) LC followed by
on-line RPLC-MS/MS. To avoid cross-contamination of samples,
both reverse phase (RP) and SCX columns were new and dedicated
to either NOD.DQ8 or NOD.C3 peptide analysis.
Initially, the dried extracts were resuspended in 60 µl 0.1% TFA,
desalted, and further purified using 3 ZipTip (Millipore) pipette
tips containing C18 RP media per the manufacturer’s protocol.
Three elutions were performed, each using 30 µl 50:50 acetonitrile (CH3CN)/H20, in 0.1% TFA, providing 90 µl elution for each
extract. The eluent was completely dried and resuspended in 55 µl
3% CH3CN, 97% H20, 0.1% formic acid (solvent A for RPLC).
Five microliters of sample was loaded onto a silica capillary column with a PicoFrit tip (New Objective Inc.) packed in-house with
C18 RP material (Delta-Pak, 0.075 × 100 mm, 5 µm, 300 Å; Waters
Corp.). The gradient, pumped using a Waters CapLC (Waters Corp.),
was from 0% solvent B (97% CH3CN, 3% H2O, 0.1% FA) to 5% solvent
B over 3 minutes, then to 50% solvent B over 70 minutes. Eluent
flow was approximately 5 µl/min and split before the column at an
approximately 1:25 ratio to maintain a flow rate at the tip of 250
nl/min. Flow was directed into the entrance of the heated capillary
of an LCQ-Deca Quadrupole ion-trap mass spectrometer (Thermo
Electron Corp.) equipped with a custom-built nanospray source.
MS and dependent-scan mode MS/MS were performed using
the mass spectrometer under the control of Xcalibur 1.3 software
(Xcalibur Software Inc.). For MS, the scan range was 600–1,400
1. Castano, L., and Eisenbarth, G.S. 1990. Type-I diabetes: a chronic autoimmune disease of human,
mouse, and rat [review]. Annu. Rev. Immunol.
8:647–679.
2. Wicker, L.S., Todd, J.A., and Peterson, L.B. 1995.
Genetic control of autoimmune diabetes in the
NOD mouse. Annu. Rev. Immunol. 13:179–200.
3. McDevitt, H., Singer, S., and Tisch, R. 1996. The
role of MHC class II genes in susceptibility and
resistance to type I diabetes mellitus in the NOD
mouse. Horm. Metab. Res. 28:287–288.
4. Kikutani, H., and Makino, S. 1992. The murine
autoimmune diabetes model: NOD and related
strains [review]. Adv. Immunol. 51:285–322.
5. Acha-Orbea, H., and McDevitt, H.O. 1987. The first
external domain of the nonobese diabetic mouse
class II I-A beta chain is unique. Proc. Natl. Acad. Sci.
U. S. A. 84:2435–2439.

mass/charge ratio (m/z) in the profile mode. For MS/MS, a scan
range of 600–1,400 m/z in centroid mode was used for the MS,
and the MS/MS range was from 30% of the mass/charge ratio of the
parent ion to 2,000 m/z. The isotope clusters of parent ions were
dynamically selected and isolated with a 2.0-m/z window. The collision energy was set to 28% of the maximum, which is approximately 5 eV. For detection of peptides, the mass spectrometer
selected peptides based on their signal intensity. In such experiments, the first and second most abundant ions were analyzed in
the first run, and the third and fourth most abundant ions were
analyzed in a subsequent run.
After RP-LCMS and MS/MS analysis, the remainder of the
sample (∼40 µl) was dried to completion and resuspended in 20 µl
solvent C (30% acetonitrile; pH to 3.5 with FA). Ten microliters
was analyzed by SCX using an Ultra-Plus II LC with flow split to
5 µl/min and a PolySulfoethyl column (15 cm × 320 µm; MicroTech Scientific Inc.). The gradient was from 0% solvent D (30%
CH3CN, 01% FA, 1M ammonium acetate) to 25% solvent B in 35
minutes, to 50% solvent B at 50 minutes, to 100% solvent B at 65
minutes. Ten 7-minute fractions were collected, dried down, and
resuspended in 10 µl 3% CH3CN, 0.1% formic acid. Five microliters was injected for on-line RPLC electrospray ionization–MS as
described above using data-dependent scanning fragmentation of
the 2 most abundant ions.
All product ion spectra were analyzed, and peptide sequences
were determined automatically using Mascot software (Matrix
Science Ltd.). All the automatically determined sequences were
manually verified against the experimental product ion spectra.
The relative abundance of each peptide ion was calculated as previously described (13, 14).
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